Ocular Therapeutix, Inc. (OCUL)
7.38
+0.18
(+2.50%)
USD |
NASDAQ |
Oct 15, 16:00
7.28
-0.10
(-1.36%)
After-Hours: 20:00
Ocular Therapeutix Cash from Operations (TTM) : -238.24M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -238.24M |
| March 31, 2026 | -226.20M |
| December 31, 2025 | -204.88M |
| September 30, 2025 | -190.06M |
| June 30, 2025 | -175.90M |
| March 31, 2025 | -145.46M |
| December 31, 2024 | -134.68M |
| September 30, 2024 | -112.52M |
| June 30, 2024 | -88.88M |
| March 31, 2024 | -84.15M |
| December 31, 2023 | -70.23M |
| September 30, 2023 | -69.92M |
| June 30, 2023 | -70.18M |
| March 31, 2023 | -60.98M |
| December 31, 2022 | -59.60M |
| September 30, 2022 | -57.80M |
| June 30, 2022 | -57.61M |
| March 31, 2022 | -66.79M |
| December 31, 2021 | -65.55M |
| September 30, 2021 | -56.64M |
| June 30, 2021 | -57.32M |
| March 31, 2021 | -52.06M |
| December 31, 2020 | -53.55M |
| September 30, 2020 | -67.37M |
| Date | Value |
|---|---|
| June 30, 2020 | -72.66M |
| March 31, 2020 | -77.05M |
| December 31, 2019 | -77.58M |
| September 30, 2019 | -71.16M |
| June 30, 2019 | -63.09M |
| March 31, 2019 | -56.14M |
| December 31, 2018 | -49.23M |
| September 30, 2018 | -45.96M |
| June 30, 2018 | -49.47M |
| March 31, 2018 | -48.37M |
| December 31, 2017 | -50.47M |
| September 30, 2017 | -47.70M |
| June 30, 2017 | -40.65M |
| March 31, 2017 | -39.32M |
| December 31, 2016 | -34.00M |
| September 30, 2016 | -35.02M |
| June 30, 2016 | -37.39M |
| March 31, 2016 | -36.12M |
| December 31, 2015 | -33.74M |
| September 30, 2015 | -30.73M |
| June 30, 2015 | -27.37M |
| March 31, 2015 | -23.35M |
| December 31, 2014 | -20.50M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| EyePoint, Inc. | -267.30M |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Eli Lilly & Co. | 28.08B |
| Corcept Therapeutics, Inc. | 109.70M |
| Veru, Inc. | -26.04M |